Rapport Financial Statements From 2010 to 2025

RAPP Stock   30.64  0.39  1.29%   
Analyzing historical trends in various income statement and balance sheet accounts from Rapport Therapeutics,'s financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Rapport Therapeutics,'s valuation are summarized below:
Market Capitalization
1.4 B
Earnings Share
(2.27)
Rapport Therapeutics, Common does not presently have any trending fundamental ratios for analysis.
Check Rapport Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rapport Therapeutics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 881 K, Interest Expense of 0.0 or Selling General Administrative of 11.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 11.44. Rapport financial statements analysis is a perfect complement when working with Rapport Therapeutics, Valuation or Volatility modules.
Check out the analysis of Rapport Therapeutics, Correlation against competitors.

Rapport Therapeutics, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets184.1 M314.9 M66.6 M
Slightly volatile
Short and Long Term Debt Total1.4 M1.5 M8.8 M
Slightly volatile
Other Current Liabilities4.4 M6.1 M1.2 M
Slightly volatile
Total Current Liabilities7.1 M8.8 M2.9 M
Slightly volatile
Property Plant And Equipment Net3.4 MMM
Slightly volatile
Accounts Payable2.2 MM1.6 M
Slightly volatile
Cash58 M56.8 M36.9 M
Slightly volatile
Non Current Assets Total3.7 M5.1 M1.1 M
Slightly volatile
Cash And Short Term Investments177.4 M305.3 M64.7 M
Slightly volatile
Common Stock Shares Outstanding216.1 M207.4 M201.2 M
Very volatile
Liabilities And Stockholders Equity184.1 M314.9 M66.6 M
Slightly volatile
Non Current Liabilities Total702 K739 K19.3 M
Pretty Stable
Other Current Assets2.9 M4.5 M767.2 K
Slightly volatile
Other Stockholder Equity451.1 M429.7 M56.7 M
Slightly volatile
Total LiabilitiesM9.5 M22.3 M
Slightly volatile
Property Plant And Equipment Gross3.8 M5.9 M1.2 M
Slightly volatile
Total Current Assets180.4 M309.8 M65.5 M
Slightly volatile
Capital Stock38.9 K37 K8.2 K
Slightly volatile
Net Working Capital173.3 M301 M62.6 M
Slightly volatile
Common Stock26.4 K37 K29.4 K
Slightly volatile
Non Currrent Assets Other284.4 K160 K509.9 K
Slightly volatile
Other Assets0.80.90.9813
Slightly volatile
Short Term Debt773.9 K737 K680.7 K
Slightly volatile

Rapport Therapeutics, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization881 K839 K126.7 K
Slightly volatile
Selling General Administrative11.6 M22.1 M3.7 M
Slightly volatile
Other Operating Expenses47.5 M83.1 M18.8 M
Slightly volatile
Research Development36 M60.9 M15.2 M
Slightly volatile
Cost Of Revenue881 K839 K126.7 K
Slightly volatile
Total Operating Expenses47.2 M82.2 M18.8 M
Slightly volatile
Net Interest Income8.1 M12.1 M3.5 M
Slightly volatile
Interest Income8.1 M12.1 M3.5 M
Slightly volatile
Selling And Marketing Expenses89.6 K100.8 K109.9 K
Slightly volatile
Reconciled Depreciation523 K839 K183.1 K
Slightly volatile
Income Tax ExpenseKK9.8 K
Slightly volatile

Rapport Therapeutics, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.3 M10.2 M1.7 M
Slightly volatile
Depreciation881 K839 K127.8 K
Slightly volatile
Other Non Cash ItemsM4.8 M4.9 M
Slightly volatile
Capital Expenditures1.6 M2.4 M582.4 K
Slightly volatile
Total Cash From Financing Activities149 M221.6 M64.5 M
Slightly volatile
End Period Cash Flow58.1 M56.9 M36.9 M
Slightly volatile
Begin Period Cash Flow55.8 M70.3 M35.1 M
Slightly volatile
Issuance Of Capital Stock201.8 M221.6 M153.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation2.722.866515.3632
Slightly volatile
Payables Turnover0.450.42940.0662
Slightly volatile
Cash Per Share1.551.47210.3657
Slightly volatile
Days Payables Outstanding80885029.3 K
Slightly volatile
Income Quality0.510.82790.3797
Slightly volatile
Net Debt To EBITDA0.680.71421.8364
Slightly volatile
Current Ratio19.0135.337319.7446
Slightly volatile
Capex Per Share0.00590.01160.0028
Slightly volatile
Interest Debt Per Share0.00680.00710.0449
Slightly volatile
Debt To Assets0.00450.00470.2697
Slightly volatile
Days Of Payables Outstanding80885029.3 K
Slightly volatile
Ebt Per Ebit1.080.94281.0213
Pretty Stable
Long Term Debt To Capitalization0.280.310.3418
Slightly volatile
Quick Ratio19.0135.337319.7446
Slightly volatile
Net Income Per E B T0.80.90.9815
Slightly volatile
Cash Ratio12.176.479416.8873
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.171.03711.0879
Very volatile
Debt Ratio0.00450.00470.2697
Slightly volatile

Rapport Therapeutics, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.3 B3.7 B4.1 B
Slightly volatile
Enterprise Value4.2 B3.6 B4.1 B
Slightly volatile

Rapport Fundamental Market Drivers

About Rapport Therapeutics, Financial Statements

Rapport Therapeutics, shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Rapport Therapeutics, investors may analyze each financial statement separately, they are all interrelated. The changes in Rapport Therapeutics,'s assets and liabilities, for example, are also reflected in the revenues and expenses on on Rapport Therapeutics,'s income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.3 M-2.4 M
Cost Of Revenue839 K881 K

Pair Trading with Rapport Therapeutics,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rapport Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rapport Therapeutics, will appreciate offsetting losses from the drop in the long position's value.

Moving against Rapport Stock

  0.75002332 Zhejiang Xianju PharPairCorr
  0.73HCM HUTCHMED ChinaPairCorr
  0.66603676 Tibet Weixinkang MedicinePairCorr
  0.55603139 Shaanxi Kanghui PharmPairCorr
  0.55600381 Qinghai Spring MedicinalPairCorr
The ability to find closely correlated positions to Rapport Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rapport Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rapport Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rapport Therapeutics, Common to buy it.
The correlation of Rapport Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rapport Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rapport Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rapport Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Rapport Stock Analysis

When running Rapport Therapeutics,'s price analysis, check to measure Rapport Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics, is operating at the current time. Most of Rapport Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics,'s price. Additionally, you may evaluate how the addition of Rapport Therapeutics, to your portfolios can decrease your overall portfolio volatility.